Research advances in plant-made flavivirus antigens

Biotechnology Advances

Volumn 30, Issue 6, 2012, Pages 1493-1505

  Martinez C A ^a   Giulietti, A M ^a   Rodriguez Talou J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Antigens; Flavivirus; Molecular farming; Recombinant protein

Indexed keywords

ANTI-VIRAL DRUGS; CONTROL MEASURES; FLAVIVIRUS; GLOBALISATION; HUMAN POPULATION; MOLECULAR FARMING; PLANT SYSTEMS; PREVENTIVE MEASURES; RESEARCH EFFORTS; SUBUNIT VACCINE; VACCINE DEVELOPMENT; VECTOR CONTROLS; VECTOR-BORNE DISEASE;

ANTIGENS; DEVELOPING COUNTRIES; DISEASE CONTROL; PRODUCTION PLATFORMS; RECOMBINANT PROTEINS; RESEARCH; VIRUSES;

VACCINES;

SUBUNIT VACCINE; VIRUS ANTIGEN; VIRUS VACCINE;

ANTIGEN; BIOTECHNOLOGY; DENGUE FEVER; DISEASE SPREAD; DISEASE VECTOR; DRUG DEVELOPMENT; GLOBALIZATION; MOLECULAR ANALYSIS; PHARMACEUTICAL INDUSTRY; PROTEIN; RECOMBINATION; RESEARCH AND DEVELOPMENT; RESEARCH WORK; URBANIZATION; VACCINATION; VACCINE; VIRUS; WEST NILE VIRUS; YELLOW FEVER;

BIOTECHNOLOGY; FLAVIVIRUS; FLAVIVIRUS INFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; PLANT; REVIEW;

ANTIGENS, VIRAL; BIOTECHNOLOGY; FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; PLANTS; VACCINES, SUBUNIT; VIRAL VACCINES;

DENGUE VIRUS; FLAVIVIRUS; IXODIDA; JAPANESE ENCEPHALITIS VIRUS; TICK-BORNE ENCEPHALITIS VIRUS; WEST NILE VIRUS;

EID: 84867716754     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2012.03.004     Document Type: Review

References (198)

1. Alonso-Padilla J., de Oya N.J., Blazquez A.B., Escribano-Romero E., Escribano J.M., Saiz J.C. Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease. Vaccine 2011, 29(9):1830-1835.
2. Appaiahgari M.B., Vrati S. IMOJEV: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010, 9(12):1371-1384.
3. Appaiahgari M.B., Abdin M.Z., Bansal K.C., Vrati S. Expression of Japanese encephalitis virus envelope protein in transgenic tobacco plants. J Virol Methods 2009, 162(1-2):22-29.
4. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78(22):12497-12507.
5. Aviezer D., Brill-Almon E., Shaaltiel Y., Hashmueli S., Bartfeld D., Mizrachi S., et al. A plant-derived recombinant human glucocerebrosidase enzyme-a preclinical and phase I investigation. PLoS One 2009, 4(3):e4792.
6. Barros M.C., Galasso T.G., Chaib A.J., Degallier N., Nagata T., Ribeiro B.M. Yellow fever virus envelope protein expressed in insect cells is capable of syncytium formation in lepidopteran cells and could be used for immunodetection of YFV in human sera. Virol J 2011, 8:261.
7. Beasley D.W., Barrett A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002, 76(24):13097-13100.
8. Beckett C.G., Tjaden J., Burgess T., Danko J.R., Tamminga C., Simmons M., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29(5):960-968.
9. Biemelt S., Sonnewald U., Galmbacher P., Willmitzer L., Muller M. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 2003, 77(17):9211-9220.
10. Bisht H., Chugh D.A., Raje M., Swaminathan S.S., Khanna N. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J Biotechnol 2002, 99(2):97-110.
11. Bonafe N., Rininger J.A., Chubet R.G., Foellmer H.G., Fader S., Anderson J.F., et al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells. Vaccine 2009, 27(2):213-222.
12. CDC Epidemic/Epizootic West Nile Virus in the United States: Guidelines for Surveillance, Prevention, and Control. 3rd Revision 2003, 1-78.
13. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358(9276):121-122.
14. Chang D.C., Liu W.J., Anraku I., Clark D.C., Pollitt C.C., Suhrbier A., et al. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol 2008, 26(5):571-577.
15. Chaturvedi U.C., Shrivastava R., Nagar R. Dengue vaccines: problems and prospects. Indian J Med Res 2005, 121(5):639-652.
16. Chavez J.H., Silva J.R., Amarilla A.A., Moraes Figueiredo L.T. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals 2010, 38(6):613-618.
17. Chen Q., He J., Phoolcharoen W., Mason H.S. Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants. Hum Vaccin 2011, 7(3):331-338.
18. Chu J.H., Chiang C.C., Ng M.L. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 2007, 178(5):2699-2705.
19. Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010, 28(15):2705-2715.
20. Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011, 23(3):391-398.
21. Coller B.A., Clements D.E., Bett A.J., Sagar S.L., Ter Meulen J.H. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011, 29(42):7267-7275.
22. Crill W.D., Chang G.J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 2004, 78(24):13975-13986.
23. Daniell H., Singh N.D., Mason H., Streatfield S.J. Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 2009, 14(12):669-679.
24. D'Aoust M.A., Couture M.M., Charland N., Trepanier S., Landry N., Ors F., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8(5):607-619.
25. Dauphin G., Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 2007, 25(30):5563-5576.
26. Davies H.M. Review article: commercialization of whole-plant systems for biomanufacturing of protein products: evolution and prospects. Plant Biotechnol J 2010, 8(8):845-861.
27. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001, 75(9):4040-4047.
28. Davoodi-Semiromi A., Samson N., Daniell H. The green vaccine: a global strategy to combat infectious and autoimmune diseases. Hum Vaccin 2009, 5(7):488-493.
29. de Sousa Sampaio P.N., Neto H., Poejo P., Serrazina S.M.T., Soares Pais M.S. Overexpression and characterization of cyprosin B in transformed suspension cells of Cynara cardunculus. Plant Cell Tissue Organ Cult 2010, 101:311-321.
30. Despres P., Dietrich J., Girard M., Bouloy M. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice. J Gen Virol 1991, 72(Pt 11):2811-2816.
31. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005, 191(2):207-214.
32. Diamond M.S. Evasion of innate and adaptive immunity by flaviviruses. Immunol Cell Biol 2003, 81(3):196-206.
33. Diamond M.S., Shrestha B., Marri A., Mahan D., Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003, 77(4):2578-2586.
34. Duggan S.T., Plosker G.L. Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO]. Drugs 2009, 69(1):115-122.
35. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006, 2(6):255-260.
36. Eckels K.H., Dubois D.R., Summers P.L., Schlesinger J.J., Shelly M., Cohen S., et al. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection. Am J Trop Med Hyg 1994, 50(4):472-478.
37. Faye L., Gomord V. Success stories in molecular farming-a brief overview. Plant Biotechnol J 2010, 8(5):525-528.
38. Feighny R., Burrous J., McCown J., Hoke C., Putnak R. Purification of native dengue-2 viral proteins and the ability of purified proteins to protect mice. Am J Trop Med Hyg 1992, 47(4):405-412.
39. Fischer M., Lindsey N., Staples J.E., Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-1):1-27.
40. Fujita H., Sumiyoshi H., Mori C., Manabe S., Takagi M., Yoshida I., et al. Studies in the development of Japanese encephalitis vaccine: expression of virus envelope glycoprotein V3 (E) gene in yeast. Bull World Health Organ 1987, 65(3):303-308.
41. Garmendia A.E., Van Kruiningen H.J., French R.A. The West Nile virus: its recent emergence in North America. Microbes Infect 2001, 3(3):223-229.
42. Ghosh D., Basu A. Japanese encephalitis-a pathological and clinical perspective. PLoS Negl Trop Dis 2009, 3(9):e437.
43. Gleba Y., Klimyuk V., Marillonnet S. Magnifection-a new platform for expressing recombinant vaccines in plants. Vaccine 2005, 23(17-18):2042-2048.
44. Goncalvez A.P., Engle R.E., St Claire M., Purcell R.H., Lai C.J. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 2007, 104(22):9422-9427.
45. Goncharova E.P., Ryzhikov A.B., Bulychev L.E., Sizov A.A., Lebedev L.R., Poryvaev V.D., et al. A study of systems for delivering antigens and plasmid DNA for intranasal immunization against tick-borne encephalitis virus. Wien Klin Wochenschr 2002, 114(13-14):630-635.
46. Goto A., Yoshii K., Obara M., Ueki T., Mizutani T., Kariwa H., et al. Role of the N-linked glycans of the prM and E envelope proteins in tick-borne encephalitis virus particle secretion. Vaccine 2005, 23(23):3043-3052.
47. Gould E.A., Solomon T. Pathogenic flaviviruses. Lancet 2008, 371(9611):500-509.
48. Grgic-Vitek M., Avsic-Zupanc T., Klavs I. Tick-borne encephalitis after vaccination: vaccine failure or misdiagnosis. Vaccine 2010, 28(46):7396-7400.
49. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998, 11(3):480-496.
50. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
51. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010, 6(9).
52. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(42):7229-7241.
53. Guzman M.G., Alvarez M., Rodriguez-Roche R., Bernardo L., Montes T., Vazquez S., et al. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 2007, 13(2):282-286.
54. Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 2010, 9(2):137-147.
55. Halstead S.B. Dengue. Lancet 2007, 370(9599):1644-1652.
56. Hayes E.B., Komar N., Nasci R.S., Montgomery S.P., O'Leary D.R., Campbell G.L. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005, 11(8):1167-1173.
57. He J., Lai H., Brock C., Chen Q. A novel system for rapid and cost-effective production of detection and diagnostic reagents of West Nile virus in plants. J Biomed Biotechnol 2012, 2012:106783.
58. Heinz F.X., Collett M.S., Purcell R.H., Gould E.A., Howard C.R., Houghton M., Moorman R.J.M., Rice C.M., Thiel H.J. Family flaviviridae. 7th International Committee for the Taxonomy of Viruses 2000, Academic Press, San Diego, California. H.V. Regenmortel, C.M. Fauquet, D.H.L. Bishop, E. Carstens, M.K. Estes, S. Lemon, J. Maniloff, M.A. Mayo, D. McGeogch, C.R. Pringle, R.B. Wickner (Eds.).
59. Hellwig S., Drossard J., Twyman R.M., Fischer R. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004, 22(11):1415-1422.
60. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2011, 9(3):299-307.
61. Holbrook M.R., Shope R.E., Barrett A.D. Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses. J Clin Microbiol 2004, 42(9):4101-4110.
62. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 2005, 23(21):2689-2695.
63. Huang T.-K., McDonald K.A. Bioreactor engineering for recombinant protein production in plant cell suspension cultures. Biochem Eng J 2009, 45:168-184.
64. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 2003, 77(21):11436-11447.
65. Huang Z., Elkin G., Maloney B.J., Beuhner N., Arntzen C.J., Thanavala Y., et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 2005, 23(15):1851-1858.
66. Huang Z., Santi L., LePore K., Kilbourne J., Arntzen C.J., Mason H.S. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 2006, 24(14):2506-2513.
67. Huang Z., Chen Q., Hjelm B., Arntzen C., Mason H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol Bioeng 2009, 103(4):706-714.
68. Iglesias M.C., Frenkiel M.P., Mollier K., Souque P., Despres P., Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 2006, 8(3):265-274.
69. Ishikawa T., Wang G., Widman D.G., Infante E., Winkelmann E.R., Bourne N., et al. Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene. Vaccine 2011, 29(43):7444-7455.
70. Jaiswal S., Khanna N., Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli. Protein Expr Purif 2004, 33(1):80-91.
71. Kaiser R. The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98: a prospective study of 656 patients. Brain 1999, 122(Pt 11):2067-2078.
72. Kaiser J. Is the drought over for pharming?. Science 2008, 320(5875):473-475.
73. Kalayanarooj S., Nimmannitya S. Is dengue severity related to nutritional status?. Southeast Asian J Trop Med Public Health 2005, 36(2):378-384.
74. Kanagaraj A.P., Verma D., Daniell H. Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplasts. Plant Mol Biol 2011, 76(3-5):323-333.
75. Kanesa-thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19(23-24):3179-3188.
76. Kelly E.P., Greene J.J., King A.D., Innis B.L. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 2000, 18(23):2549-2559.
77. Kim T.G., Kim M.Y., Yang M.S. Cholera toxin B subunit-domain III of dengue virus envelope glycoprotein E fusion protein production in transgenic plants. Protein Expr Purif 2010, 74(2):236-241.
78. King N.J., Getts D.R., Getts M.T., Rana S., Shrestha B., Kesson A.M. Immunopathology of flavivirus infections. Immunol Cell Biol 2007, 85(1):33-42.
79. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38(2):411-419.
80. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997, 15(5):547-552.
81. Kofler R.M., Heinz F.X., Mandl C.W. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence. J Virol 2002, 76(7):3534-3543.
82. Konishi E., Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 2002, 20(7-8):1058-1067.
83. Konishi E., Fujii A., Mason P.W. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles. J Virol 2001, 75(5):2204-2212.
84. Koraka P., Martina B.E., Osterhaus A.D. Bioinformatics in new generation flavivirus vaccines. J Biomed Biotechnol 2010, 2010:864029.
85. Kumar R., Mathur A., Kumar A., Sharma S., Chakraborty S., Chaturvedi U.C. Clinical features & prognostic indicators of Japanese encephalitis in children in Lucknow (India). Indian J Med Res 1990, 91:321-327.
86. Kumar R., Tripathi P., Singh S., Bannerji G. Clinical features in children hospitalized during the 2005 epidemic of Japanese encephalitis in Uttar Pradesh, India. Clin Infect Dis 2006, 43(2):123-131.
87. Kyle J.L., Harris E. Global spread and persistence of dengue. Annu Rev Microbiol 2008, 62:71-92.
88. Labeaud A.D., Bashir F., King C.H. Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections. Popul Health Metr 2011, 9(1):1.
89. LaFleur C., Granados J., Vargas-Alarcon G., Ruiz-Morales J., Villarreal-Garza C., Higuera L., et al. HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever. Hum Immunol 2002, 63(11):1039-1044.
90. Lai H., He J., Engle M., Diamond M.S., Chen Q. Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol J 2011, 10(1):95-104.
91. Ledizet M., Kar K., Foellmer H.G., Wang T., Bushmich S.L., Anderson J.F., et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine 2005, 23(30):3915-3924.
92. Lee E., Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J Virol 2008, 82(12):6024-6033.
93. Lee L.A., Wang Q. Adaptations of nanoscale viruses and other protein cages for medical applications. Nanomedicine 2006, 2(3):137-149.
94. Leonova G.N., Ternovoi V.A., Pavlenko E.V., Maistrovskaya O.S., Protopopova E.V., Loktev V.B. Evaluation of vaccine Encepur Adult for induction of human neutralizing antibodies against recent Far Eastern subtype strains of tick-borne encephalitis virus. Vaccine 2007, 25(5):895-901.
95. Lieberman M.M., Clements D.E., Ogata S., Wang G., Corpuz G., Wong T., et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 2007, 25(3):414-423.
96. Lin C.W., Liu K.T., Huang H.D., Chen W.J. Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus. Biotechnol Lett 2008, 30(2):205-214.
97. Lindenbach B.D., Thiel H.J., Rice C.M. Flaviviridae: the viruses and their replication. Fields Virology 2007, 1101-1152. Lippincott-Raven, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
98. Liu W., Jiang H., Zhou J., Yang X., Tang Y., Fang D., et al. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 2010, 40(1):53-59.
99. Loew-Baselli A., Poellabauer E.M., Pavlova B.G., Fritsch S., Firth C., Petermann R., et al. Prevention of tick-borne encephalitis by FSME-IMMUN((R)) vaccines: review of a clinical development programme. Vaccine 2011, 29(43):7307-7319.
100. Lorenz I.C., Kartenbeck J., Mezzacasa A., Allison S.L., Heinz F.X., Helenius A. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 2003, 77(7):4370-4382.
101. Ma J.K., Drake P.M., Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003, 4(10):794-805.
102. Marillonnet S., Giritch A., Gils M., Kandzia R., Klimyuk V., Gleba Y. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci U S A 2004, 101(18):6852-6857.
103. Marillonnet S., Thoeringer C., Kandzia R., Klimyuk V., Gleba Y. Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol 2005, 23(6):718-723.
104. Martin M., Tsai T.F., Cropp B., Chang G.J., Holmes D.A., Tseng J., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(9276):98-104.
105. Martina B.E., Koraka P., van den Doel P., van Amerongen G., Rimmelzwaan G.F., Osterhaus A.D. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 2008, 26(2):153-157.
106. Martinez C.A., Topal E., Giulietti A.M., Talou J.R., Mason H. Exploring different strategies to express Dengue virus envelope protein in a plant system. Biotechnol Lett 2010, 32(6):867-875.
107. Martinez C.A., Giulietti A.M., Rodriguez Talou J. Expression of a KDEL-tagged dengue virus protein in cell suspension cultures of Nicotiana tabacum and Morinda citrifolia. Plant Cell Tissue Organ Cult 2011, 107(1):91-100.
108. McArthur J.H., Durbin A.P., Marron J.A., Wanionek K.A., Thumar B., Pierro D.J., et al. Phase I clinical evaluation of rDEN4Delta30-200, 201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008, 79(5):678-684.
109. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 2005, 4(4):553-574.
110. Monath T.P. Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med 2007, 357(22):2222-2225.
111. Monath T.P. Treatment of yellow fever. Antiviral Res 2008, 78(1):116-124.
112. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188(8):1213-1230.
113. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A 2006, 103(17):6694-6699.
114. Monath T.P., Fowler E., Johnson C.T., Balser J., Morin M.J., Sisti M., et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med 2011, 364(14):1326-1333.
115. Monath T.P., Lee C.K., Julander J.G., Brown A., Beasley D.W., Watts D.M., et al. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 2011, 28(22):3827-3840.
116. Morens D.M., Folkers G.K., Fauci A.S. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430(6996):242-249.
117. Mune M., Rodriguez R., Ramirez R., Soto Y., Sierra B., Rodriguez Roche R., et al. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Arch Virol 2003, 148(11):2267-2273.
118. Murgue B., Zeller H., Deubel V. The ecology and epidemiology of West Nile virus in Africa, Europe and Asia. Curr Top Microbiol Immunol 2002, 267:195-221.
119. Murrell S., Wu S.C., Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv 2011, 29(2):239-247.
120. Mutoh E., Ishikawa T., Takamizawa A., Kurata T., Sata T., Kojima A. Japanese encephalitis subunit vaccine composed of virus-like envelope antigen particles purified from serum-free medium of a high-producer J12#26 cell clone. Vaccine 2004, 22(20):2599-2608.
121. Nguyen T.P., Kikuchi M., Vu T.Q., Do Q.H., Tran T.T., Vo D.T., et al. Protective and enhancing HLA alleles, HLA-DRB1 0901 and HLA-A 24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2008, 2(10):e304.
122. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol 2003, 11(9):438-444.
123. Ohtaki N., Takahashi H., Kaneko K., Gomi Y., Ishikawa T., Higashi Y., et al. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate. Vaccine 2010, 28(40):6588-6596.
124. Peny J.M., Gleizes O., Covilard J.P. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective. Vaccine 2005, 23(37):4610-4618.
125. Petri E., Gniel D., Zent O. Tick-borne encephalitis (TBE) trends in epidemiology and current and future management. Travel Med Infect Dis 2010, 8(4):233-245.
126. Pletnev A.G., Claire M.S., Elkins R., Speicher J., Murphy B.R., Chanock R.M. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003, 314(1):190-195.
127. Pripuzova N.S., Tereshkina N.V., Gmyl L.V., Dzhivanyan T.I., Rumyantsev A.A., Romanova L., et al. Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis. J Med Virol 2009, 81(10):1777-1785.
128. Pugachev K.V., Guirakhoo F., Trent D.W., Monath T.P. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol 2003, 33(5-6):567-582.
129. Pugachev K.V., Guirakhoo F., Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005, 18(5):387-394.
130. Pulmanausahakul R., Khakpoor A., Smith D.R. The development of flavivirus vaccines. Afr J Biotechnol 2010, 9(4):409-415.
131. Pumpens P., Grens E. Hepatitis B core particles as a universal display model: a structure-function basis for development. FEBS Lett 1999, 442(1):1-6.
132. Purdy D.E., Chang G.J. Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein. Virology 2005, 333(2):239-250.
133. Putnak J.R., Schlesinger J.J. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol 1990, 71(Pt 8):1697-1702.
134. Putnak R., Feighny R., Burrous J., Cochran M., Hackett C., Smith G., et al. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 1991, 45(2):159-167.
135. Qiao M., Ashok M., Bernard K.A., Palacios G., Zhou Z.H., Lipkin W.I., et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis 2004, 190(12):2104-2108.
136. Qing M., Liu W., Yuan Z., Gu F., Shi P.Y. A high-throughput assay using dengue-1 virus-like particles for drug discovery. Antiviral Res 2011, 86(2):163-171.
137. Rauthan M., Kaur R., Appaiahgari M.B., Vrati S. Oral immunization of mice with Japanese encephalitis virus envelope protein synthesized in Escherichia coli induces anti-viral antibodies. Microbes Infect 2004, 6(14):1305-1311.
138. Regnard G.L., Halley-Stott R.P., Tanzer F.L., Hitzeroth I.I., Rybicki E.P. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J 2010, 8(1):38-46.
139. Rendi-Wagner P. Advances in vaccination against tick-borne encephalitis. Expert Rev Vaccines 2008, 7(5):589-596.
140. Rey F.A., Heinz F.X., Mandl C., Kunz C., Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995, 375(6529):291-298.
141. Rice C.M., Lenches E.M., Eddy S.R., Shin S.J., Sheets R.L., Strauss J.H. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985, 229(4715):726-733.
142. Ritchie S.A., Rochester W. Wind-blown mosquitoes and introduction of Japanese encephalitis into Australia. Emerg Infect Dis 2001, 7(5):900-903.
143. Rybicki E.P. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010, 8(5):620-637.
144. Saad M., Youssef S., Kirschke D., Shubair M., Haddadin D., Myers J., et al. Acute flaccid paralysis: the spectrum of a newly recognized complication of West Nile virus infection. J Infect 2005, 51(2):120-127.
145. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002, 66(3):264-272.
146. Saejung W., Puttikhunt C., Prommool T., Sojikul P., Tanaka R., Fujiyama K., et al. Enhancement of recombinant soluble dengue virus 2 envelope domain III protein production in Escherichia coli trxB and gor double mutant. J Biosci Bioeng 2006, 102(4):333-339.
147. Saejung W., Fujiyama K., Takasaki T., Ito M., Hori K., Malasit P., et al. Production of dengue 2 envelope domain III in plant using TMV-based vector system. Vaccine 2007, 25(36):6646-6654.
148. Santi L., Huang Z., Mason H. Virus-like particles production in green plants. Methods 2006, 40(1):66-76.
149. Schafer B., Holzer G.W., Joachimsthaler A., Coulibaly S., Schwendinger M., Crowe B.A., et al. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One 2011, 6(9):e24505.
150. Schalich J., Allison S.L., Stiasny K., Mandl C.W., Kunz C., Heinz F.X. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol 1996, 70(7):4549-4557.
151. Schodel F., Peterson D., Hughes J., Wirtz R., Milich D. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. Presentation of foreign epitopes. J Biotechnol 1996, 44(1-3):91-96.
152. Scholle F., Girard Y.A., Zhao Q., Higgs S., Mason P.W. Trans-packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors. J Virol 2004, 78(21):11605-11614.
153. Seligman S.J., Gould E.A. Live flavivirus vaccines: reasons for caution. Lancet 2004, 363(9426):2073-2075.
154. Shih S.M., Doran P.M. Foreign protein production using plant cell and organ cultures: advantages and limitations. Biotechnol Adv 2009, 27(6):1036-1042.
155. Sim A.C., Lin W., Tan G.K., Sim M.S., Chow V.T., Alonso S. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine 2008, 26(9):1145-1154.
156. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80(19):9577-9585.
157. Smith M.L., Mason H.S., Shuler M.L. Hepatitis B surface antigen (HBsAg) expression in plant cell culture: kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol Bioeng 2002, 80(7):812-822.
158. Solomon T., Mallewa M. Dengue and other emerging flaviviruses. J Infect 2001, 42(2):104-115.
159. Solomon T., Dung N.M., Kneen R., Gainsborough M., Vaughn D.W., Khanh V.T. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000, 68(4):405-415.
160. Spohn G., Jennings G.T., Martina B.E., Keller I., Beck M., Pumpens P., et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 2010, 7:146.
161. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(RR-7):1-27.
162. Staropoli I., Frenkiel M.P., Megret F., Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 1997, 15(17-18):1946-1954.
163. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 2005, 83(4):308-314.
164. Streatfield S.J. Approaches to achieve high-level heterologous protein production in plants. Plant Biotechnol J 2007, 5(1):2-15.
165. Su W. Bioreactor engineering for recombinant protein production using plant cell suspension culture. Plant Tissue Culture Engineering 2006, 6:135-159.
166. Sugrue R.J., Cui T., Xu Q., Fu J., Chan Y.C. The production of recombinant dengue virus E protein using Escherichia coli and Pichia pastoris. J Virol Methods 1997, 69(1-2):159-169.
167. Sugrue R.J., Fu J., Howe J., Chan Y.C. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles. J Gen Virol 1997, 78(Pt 8):1861-1866.
168. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69(6 Suppl):24-31.
169. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009, 5(1):33-40.
170. Sun E., Zhao J., Liu N., Yang T., Xu Q., Qin Y., et al. Comprehensive mapping of common immunodominant epitopes in the west Nile virus nonstructural protein 1 recognized by avian antibody responses. PLoS One 2012, 7(2):e31434.
171. Teoh P.G., Ooi A.S., AbuBakar S., Othman R.Y. Virus-specific read-through codon preference affects infectivity of chimeric cucumber green mottle mosaic viruses displaying a dengue virus epitope. J Biomed Biotechnol 2009, 2009:781712.
172. Theiler M., Smith H.H. The use of Yellow Fever Virus modified by in vitro cultivation for human immunization. J Exp Med 1937, 65(6):787-800.
173. Thisyakorn U., Nimmannitya S. Nutritional status of children with dengue hemorrhagic fever. Clin Infect Dis 1993, 16(2):295-297.
174. Tiwari S., Verma P.C., Singh P.K., Tuli R. Plants as bioreactors for the production of vaccine antigens. Biotechnol Adv 2009, 27(4):449-467.
175. Twyman R.M., Stoger E., Schillberg S., Christou P., Fischer R. Molecular farming in plants: host systems and expression technology. Trends Biotechnol 2003, 21(12):570-578.
176. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97.
177. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181(1):2-9.
178. Verma S.K., Gupta N., Pattnaik P., Babu J.P., Rao P.V., Kumar S. Antibodies against refolded recombinant envelope protein (domain III) of Japanese encephalitis virus inhibit the JEV infection to Porcine Stable Kidney cells. Protein Pept Lett 2009, 16(11):1334-1341.
179. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24(27-28):5571-5583.
180. Volk D.E., May F.J., Gandham S.H., Anderson A., Von Lindern J.J., Beasley D.W., et al. Structure of yellow fever virus envelope protein domain III. Virology 2009, 394(1):12-18.
181. Wang Y., Deng H., Zhang X., Xiao H., Jiang Y., Song Y., et al. Generation and immunogenicity of Japanese encephalitis virus envelope protein expressed in transgenic rice. Biochem Biophys Res Commun 2009, 380(2):292-297.
182. Warzecha H., Mason H.S., Lane C., Tryggvesson A., Rybicki E., Williamson A.L., et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003, 77(16):8702-8711.
183. Webster D.P., Farrar J., Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009, 9(11):678-687.
184. White N.J. Variation in virulence of dengue virus. Lancet 1999, 354(9188):1401-1402.
185. WHO Japanese encephalitis virus vaccines. Wkly Epidemiol Rec 2006, 81(34/35):325-340.
186. WHO Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Immunization, vaccines and biological 2008, 1-55.
187. Wiedermann U. Tick borne encephalitis TBE-vaccination in non-endemic countries. Travel Med Infect Dis 2010, 8(4):251-256.
188. Wiggan O., Livengood J.A., Silengo S.J., Kinney R.M., Osorio J.E., Huang C.Y., et al. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine 2011, 29(43):7456-7462.
189. Williams K.L., Zompi S., Beatty P.R., Harris E. A mouse model for studying dengue virus pathogenesis and immune response. Ann N Y Acad Sci 2009, 1171(Suppl. 1):E12-E23.
190. Wu H.H., Chen C.T., Lin Y.L., Lee S.T. Sub-fragments of the envelope gene are highly protective against the Japanese encephalitis virus lethal infection in DNA priming-protein boosting immunization strategies. Vaccine 2004, 22(5-6):793-800.
191. Xu J., Dolan M.C., Medrano G., Cramer C.L., Weathers P.J. Green factory: Plants as bioproduction platforms for recombinant proteins. Biotechnol Adv 2012, 30(5):1171-1184.
192. Yoo J.W., Irvine D.J., Discher D.E., Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov 2011, 10(7):521-535.
193. Zent O., Schwarz T.F., Plentz A., Banzhoff A., Jilg W. TBE booster immunization in adults-first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Int J Med Microbiol 2004, 293(Suppl. 37):134-138.
194. Zent O., Wittermann C., Banzhoff A., Plentz A., Jilg W. New TBE vaccine formulations-free of proteineous stabilizer and preservatives. Overview of clinical studies and first year post-marketing experience. MMW Fortschr Med 2004, 146(3-4):43.
195. Zhang Y., Zhang W., Ogata S., Clements D., Strauss J.H., Baker T.S., et al. Conformational changes of the flavivirus E glycoprotein. Structure 2004, 12(9):1607-1618.
196. Zhang F., Ma W., Zhang L., Aasa-Chapman M., Zhang H. Expression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell line. Virol J 2007, 4:17.
197. Zhang Z.S., Yan Y.S., Weng Y.W., Huang H.L., Li S.Q., He S., et al. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J Virol Methods 2007, 143(2):125-131.
198. Zhang S., Liang M., Gu W., Li C., Miao F., Wang X., et al. Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol J 2011, 8:333.